Completed PHASE2 INTERVENTIONAL NCT00066989

Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates

A Double Blind, Randomized, Multicenter Stratified Study to Assess the Safety of an Intravenous Staphylococcus Aureus Immune Globulin (Human) [Altastaph] in Low-Birth-Weight-Neonates

Sponsor: Nabi Biopharmaceuticals

Conditions Staphylococcal Infections

Interventions Staphylococcus aureus Immune Globulin (Human) 5%

Updated 6 times since 2017 Last updated: May 10, 2012 Started: Jul 31, 2003 Primary completion: Aug 31, 2004 Completion: Aug 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00066989, this PHASE2 trial focuses on Staphylococcal Infections and remains completed. Sponsored by Nabi Biopharmaceuticals, it has been updated 6 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nabi Biopharmaceuticals

Data source: Nabi Biopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.